Browsing Depressive Disorders by Title
Now showing items 72-91 of 111
-
Pramipexole Enhances Reward Learning by Preserving Value Estimates
(2022-01)Background: Dopamine D2-like receptor agonists show promise as treatments for depression. They are thought to act by altering how individuals learn from rewarding experiences. However, the nature of these reward learning ... -
Pramipexole for the Treatment of Depression: Efficacy and Mechanisms
(2023-11)Dopaminergic mechanisms are a plausible treatment target for patients with clinical depression but are relatively underexplored in conventional antidepressant medications. There is continuing interest in the potential ... -
Precision biomarkers for mood disorders based on brain imaging
(2020-10)Mood disorders are a global public health problem because of their high prevalence, chronicity, and recurrence throughout the lifespan as well as increased risk of mortality.123 They also impose a heavy economic burden on ... -
Predicting Antidepressant Treatment Response Using Functional Brain Controllability Analysis
(2023-03)Introduction: For decades, predicting response to the antidepressant medication has been a critical unmet need in depression treatment in clinic, and a technical challenge in depression research. Methods: In this study, ... -
Predicting treatment effects in unipolar depression: A meta-review
(2020-08)There is increasing interest in clinical prediction models in psychiatry, which focus on developing multivariate algorithms to guide personalized diagnostic or management decisions. The main target of these models is the ... -
Predicting treatment response in depression: the role of anterior cingulate cortex
(2018)Background: Identification of biomarkers predicting therapeutic outcome to antidepressant treatment is one of the most important tasks in current research because it may transform the lengthy process of finding the right ... -
Predicting Treatment Response to Antidepressant Medication Using Early Changes in Emotional Processing.
(2019-01)Antidepressants must be taken for weeks before response can be assessed with many patients not responding to the first medication prescribed. This often results in long delays before effective treatment is started. ... -
Pro-dopaminergic pharmacological interventions for anhedonia in depression: protocol for a living systematic review of human and non-human studies
(2023-10)Anhedonia is a key symptom of depression, and it has been suggested as a potential target for future individualised treatments. However, much is unknown about how interventions enhancing dopaminergic pathways may affect ... -
Protocol for a systematic review of the pharmacological augmentation treatment guidelines for unipolar depression
(2019-11)Objectives: To provide a comprehensive overview of recommendations made by local, national and international bodies for the prescription of pharmacological augmentation therapies for TRD, to identify consistencies ... -
Psychologic Treatment of Depression Compared With Pharmacotherapy and Combined Treatment in Primary Care: A Network Meta-Analysis
(2021-05)PURPOSE Most patients with depression are treated by general practitioners, and most of those patients prefer psychotherapy over pharmacotherapy. No network meta-analyses have examined the effects of psychotherapy compared ... -
Real-world effect of antidepressants for depressive disorder in primary care: protocol of a population-based cohort study
(2020-06)Introduction Clinical guidelines recommend antidepressants as the first line of treatment for adults with moderate-to-severe depression. Randomised trials provide the best evidence on the comparative effectiveness of ... -
Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder
(2021-09)With no available response biomarkers, matching an appropriate antidepressant to an individual can be a lengthy process. Improving understanding of processes underlying treatment responsivity in depression is crucial for ... -
A retrospective examination of care pathways in individuals with treatment-resistant depression
(2021-05)Individuals with treatment-resistant depression (TRD) experience a high burden of illness. Current guidelines recommend a stepped care approach for treating depression, but the extent to which best-practice care pathways ... -
Seeing sadness: Comorbid effects of loneliness and depression on emotional face processing
(2021-05)Background/objective: Loneliness and depression are highly comorbid, and both are associated with social processing deficits. However, there is a paucity of research aimed at differentiating emotional face-processing ... -
Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials
(2022-01)Valid assessment of drug efficacy and safety requires an evidence base free of reporting bias. Using trial reports in Food and Drug Administration (FDA) drug approval packages as a gold standard, we previously found that ... -
Self-reported depression symptoms in haemodialysis patients: Bi-factor structures of two common measures and their association with clinical factors
(2018-08)Objective: To validate the factor structure of two common self-report depression tools in a large sample of haemodialysis (HD) patients and to examine their demographic and clinical correlates, including urine output, ... -
Side effect profile and comparative tolerability of 21 antidepressants in the acute treatment of major depression in adults: protocol for a network meta-analysis
(2019-05)Introduction: We have recently compared all second-generation as well as selected first-generation antidepressants in terms of efficacy and acceptability in the acute treatment of major depression. Here we present a protocol ... -
A single administration of ‘microbial’ D-alanine to healthy volunteers augments reaction to negative emotions: a comparison with D-serine
(2020-03)Background Activation of the glutamate N-methyl-D-Aspartate receptor (NMDAR) with its co-agonist D-serine has been shown to improve subjective mood in healthy volunteers. D-alanine is another potent NMDAR co-agonist which ... -
A single dose of fluoxetine reduces neural limbic responses to anger in depressed adolescents
(2019-01-21)Depression in adolescence is frequently characterised by symptoms of irritability. Fluoxetine is the antidepressant with the most favourable benefit:risk ratio profile to treat adolescent depression, but the neural ... -
Sleep deprivation as a treatment for major depressive episodes: A systematic review and meta-analysis
(2022-05)Sleep deprivation, alone or in combination with pharmacological treatment and as part of a chronotherapy package, is of potential use for people with major depressive episodes, however the evidence base is still conflicting. ...